晚期雌激素受体阳性乳腺癌的治疗进展

Progress in the treatment of estrogen receptor-positive advanced breast cancer

针对晚期雌激素受体阳性乳腺癌虽然主要使用内分泌、靶向等治疗方法,但内分泌治疗的耐药问题在临床上较常见。随着对CDK4/6、PI3K-Akt1-m TOR通路等治疗靶点和耐药机制的研究,晚期雌激素受体阳性乳腺癌的靶向治疗已成为研究热点,利用基因靶向治疗等也可能成为新的突破点,同时在如何针对不同患者选择最佳治疗方案、最佳治疗时间等问题上仍存在挑战。本文将就晚期雌激素受体阳性乳腺癌的治疗进展进行综述。

Although endocrine therapies, targeted therapies, and other methods are the main treatments for advanced estrogen receptor-positive breast cancer, the clinical treatment of endocrine resistance is more common. With the study of CDK4/6, the PI3KAKT1-mTOR signaling pathway, and other drug resistance mechanisms, targeted therapy for advanced estrogen receptor-positive breast cancer has become a popular research topic. Other treatments, such as gene therapy, may also provide new breakthroughs.How to choose the best treatment, best treatment time, and other issues for different patients remain as challenges for advanced estrogen receptor-positive breast cancer treatment.